{"url_path":"/sec/alxo/8-k/2026-06-30/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1810182/0001193125-26-290447-index.html","accession_number":"0001193125-26-290447","cik":"0001810182","ticker":"ALXO","issuer_name":"ALX ONCOLOGY HOLDINGS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1810182/0001193125-26-290447-index.html","primary_entity_key":"0001810182","primary_entity_name":"ALX ONCOLOGY HOLDINGS INC"},"word_count":152,"has_tables":true,"body_markdown":"Item 7.01 Regulation FD Disclosure.\n\nOn June 30, 2026, the Company issued a press release announcing certain matters including those described in Item 5.02. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.\n\nThe information contained in this Item 7.01, including the related information set forth in the press release attached hereto as Exhibit 99.1, is being “furnished” and shall not be deemed “filed” with the Securities and Exchange Commission for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing."}